Medical Bill Review for Infectious Disease Practices

The phrase “72-hour rule” can refer to different billing policies depending on the payer, setting, and claim type. In some contexts, it relates to services provided around a hospital admission and whether they are grouped for payment. It is not a universal rule for every infectious disease claim. Practices should review the applicable payer policy, billing arrangement, documentation, and service setting before applying it.

A focused review can examine documentation, coding, charge capture, eligibility, prior authorization, drug and infusion billing, claim submission, denials, underpayments, accounts receivable, and payer contracts. The goal is to connect a payment problem with its operational source. Reviews may also separate office visits, hospital consults, infusion services, OPAT, and drug claims so practice leaders can see where revenue is delayed or missed.

Revenue leakage can appear as under-leveled visits, missing drug or administration charges, incorrect units, unpursued balances, documentation gaps, or payer payments that do not follow contract terms. Reporting by payer, service line, and provider can reveal patterns. Tracing each gap back to documentation, coding, charge capture, authorization, workflow, or contracting helps the practice address causes instead of only correcting individual claims.

Yes. Infectious disease bill review can address infusion services, OPAT courses, specialty drugs, administration charges, medical versus pharmacy benefit issues, and authorization requirements. The review should consider how the practice acquires and bills drugs, whether documentation supports the service, and whether payments align with applicable payer terms. These details matter because infusion and OPAT can create financial exposure when claims are delayed or unreimbursed.

Payment reconciliation compares expected reimbursement with actual payer payments for applicable drug, administration, and E/M claims. The review can flag short-pays, incorrect fee schedule application, unit mismatches, NDC mismatches, and other discrepancies. Identified underpayments can then be disputed and tracked. The process also creates information about recurring payer or workflow issues that may require broader correction.

Denial management begins by grouping denials by root cause rather than treating every rejection as unrelated. Common infectious disease issues include missing authorization, drug and administration coding, medical versus pharmacy benefit confusion, and under-documented consults. Payer-specific appeals supported by clinical documentation can address individual claims, while reporting the findings to clinical, coding, and front-office teams helps prevent repeat errors.

Revenue-cycle guidance can help a practice review the workflow from referral to first dose and through final payment. Relevant areas include documentation, coding, eligibility, prior authorization, drug acquisition, infusion billing, claims follow-up, and collections. A practical review can identify decisions that need attention before or during program development, while allowing the practice to apply its own numbers instead of relying on generalized rates or margins.

No. GrowInfectiousDisease explicitly avoids publishing rates, drug acquisition costs, payment rates, or margin figures that have not been licensed and verified. Tools and guidance are designed to help practices apply their own numbers and understand the mechanics behind revenue-cycle results. Actual reimbursement remains dependent on the practice’s contracts, payer arrangements, services, documentation, coding, and operational decisions.